He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...

Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of $213.00. The company’s shares cl ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $140.00. The company’s shares ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Good morning, Boston, and Happy National Handshake Day. Here are the five things you need to know in local business news to start your busy Thursday.

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...

Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a ...

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...

In a Phase I study, previously treated pediatric SMA patients exhibited reductions in a marker of neurodegeneration after salanersen treatment.

Based on these encouraging Phase 1 data, Biogen (NASDAQ:BIIB) is engaging with regulators to advance its investigational ...

Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...